StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN), Peers on Watch Ahead of Repetha Data at ACC.17 (REGN) (ESPR) (MDCO)
March 17, 2017 6:59 AM
Amgen (NASDAQ: AMGN) and its peers were in focus ahead of data on its PCSK9 inhibitor, Repatha, which is set ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Trader Talk
Next Articles
Repatha Outcomes Data Reinforces Regeneron (REGN) Praluent Model - BTIG
March 17, 2017 11:52 AM
Medicines Co. (MDCO) Ticks Off Lows
March 17, 2017 11:42 AM
Amgen (AMGN) FOURIER Results 'Good Enough' - Cowen
March 17, 2017 11:23 AM
While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
March 17, 2017 11:05 AM
Medicines Co. (MDCO), Esperion Therapeutics (ESPR) Plunge Following Amgen's (AMGN) Repatha Data
March 17, 2017 9:04 AM